Stanford researcher criticizes FDA plans to reduce oversight of off-label drug use

Proposed guidelines from the U.S. Food and Drug Administration would allow companies to market more drugs for unapproved uses and are a step in the wrong direction, said a researcher from the Stanford University School of Medicine.